Section Arrow
GRTX.NASDAQ
- Galera Therapeutics
(Financial Status)
Quotes are at least 15-min delayed:2024/05/16 10:16 EDT
Last
 0.1871
-0.0029 (-1.53%)
Day High 
0.1899 
Prev. Close
0.19 
1-M High
0.2385 
Volume 
46.74K 
Bid
0.1851
Ask
0.189
Day Low
0.185 
Open
0.185 
1-M Low
0.1453 
Market Cap 
10.33M 
Currency USD 
P/E -- 
%Yield
10-SMA 0.18 
20-SMA 0.18 
50-SMA 0.19 
52-W High 3.59 
52-W Low 0.0853 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.33/-0.35
Enterprise Value
11.45M
Balance Sheet
Book Value Per Share
-2.41
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
JAGXJaguar Health0.2656+0.0105+4.12%-- 
SCPXScorpius Holdings0.0918+0.0141+18.15%-- 
DNAGinkgo Bioworks Holdings0.8092-0.0299-3.56%-- 
NVAXNovavax12.72-0.18-1.40%-- 
NBYNovaBay Pharmaceuticals0.0952-0.0093-8.90%-- 
Quotes are at least 15-min delayed:2024/05/16 10:16 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Galera Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer. The Firm's lead product candidate, avasopasem manganese, is a highly selective small molecule dismutase mimetic for severe oral mucositis (SOM) in patients with head and neck cancer (HNC), the reduction of esophagitis in patients with lung cancer, and the reduction of cisplatin-induced kidney damage in patients with cancer. The Firm's second product candidate, rucosopasem manganese, has been in development to augment the anti-cancer efficacy of stereotactic body radiation therapy (SBRT) in patients with non-small cell lung cancer (NSCLC) and locally advanced pancreatic cancer (LAPC).
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.